(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following the reintroduction of the “Affordable
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the Senate Judiciary Committee’s vote to pass, S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: “Today’s vote in the
Pharmacy Benefit Companies Negotiate with Big Drug Companies to Lower Prescription Drug Costs for Patients and Families Last week, the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing, “The Need to Make Insulin Affordable for All Americans,”
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that drug companies are the root cause of high prescription drug prices is one common denominator
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
Upcoming Events Events 10 Nov 10 Nov – 11 Nov Test 2021-11-10 01:00 AM – 2021-11-11 03:00 AM Online Event PCMA Spring Webinar Series 2020 The live webinar series is designed to highlight drug supply chain executives’ thoughts and strategies
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on today’s remarks by Food and Drug Administration Commissioner Scott Gottlieb, specifically those appearing to reference drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued 21 policy solutions supported by America’s pharmacy benefit managers (PBMs) aimed at reducing prescription drug costs for patients and health plan sponsors. PBMs administer prescription drug plans for more than 266 million Americans with
©2024 PCMA. All Rights Reserved.
